Notice of Results for Year Ended 31 March 2020

RNS Number : 3774G
Eco Animal Health Group PLC
24 November 2020
 

24 November 2020

ECO Animal Health Group plc

("ECO" or the "Group")

(AIM: EAH)

 

NOTICE OF RESULTS FOR YEAR ENDED 31 MARCH 2020

CONFIRMATION OF CONTINUED STRONG TRADING

 

On 11th September 2020, ECO Animal Health Group plc (the "Group") announced that the Group intended to publish its annual audited accounts for the year ended 31 March 2020 prior to 30 November 2020.  

AIM has granted the Group an additional one month extension to the publication timetable in order to manage additional work arising from auditing the Group's international operations during the Covid-19 pandemic restrictions and against the backdrop of new auditors and new accounting policies adopted at the time of the most recent interim report.  Accordingly, the Group will publish its annual audited accounts during December and prior to 31 December 2020.  The Group's AGM will be held as soon as practicable thereafter. 

The Group provided a trading update on 21 October 2020, noting that the revenue in the six months ended 30 September 2020 would be significantly ahead of management's expectations and the same period for the prior year.  The Group confirms that strong trading has continued during November and, being mindful of the continuing global uncertainties and four months remaining until the end of the financial year, it is confident of meeting market expectations.

 

Contacts:  

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)

 

020 8447 8899

 

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Alex Bond

 

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").  Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBLBDBDXDDGGS
UK 100

Latest directors dealings